Shelley Thunen Biography and Net Worth

Ms. Thunen joined RxSight, Inc. in January 2016 as our Chief Administrative Officer and has served as our Chief Financial Officer since February 2017 through July 2024 and as our Co-President & Chief Financial Officer since August 2024. From January 2013 to October 2015, Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. (NASDAQ:ELGX) From August 2010 to December 2012, Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. Prior to Alcon’s (NYSE:ALC) acquisition of LenSx, Inc. in August 2010, she served as a board member and chair of the Audit Committee from April 2008 to August 2010, as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. (NASDAQ:ILSE) in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. (NYSE:EYE) in April 2007. Ms. Thunen served on the board of directors of eyeonics, Inc. from June 2007 to February 2008, and as a board member and chair of the Audit Committee of Restoration Robotics, Inc. (NASDAQ:HAIR) from July 2015 to November 2019, prior to its acquisition by Venus Concept Inc. (NASDAQ:VERO). She also has served as a board member and Audit Committee chair of Surface Ophthalmics, Inc. since August 2020. She also serves as a board member and Audit Committee chair of Aeon Biopharma, Inc. (NYSE:AEON) since June 2023 and as a board member, Audit Committee chair and Compensation Committee member for Lenz Therapeutics, Inc. (NASDAQ: LENZ) since November 2023. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine.